The ARK Genomic Revolution ETF remains a "Buy" as it beats SPY/XLV, shows bullish breakout signals, and targets $42. Learn more about the fund.

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

On Thursday, ARK bought a total of 56,769 shares of Intellia, with 48,178 shares purchased by its ARKK ETF and 8,591 shares through its ARKG ETF. ・NTLA stock was its top 23 investment as of Dec. 31, ...

Cathie Wood's ARK sold $2.78M Twist Bioscience, bought Tempus AI & WeRide Jan 26. Full breakdown of ARK Invest's latest AI ...

In smaller moves, ARK sold 2,631 shares of Kratos Defense and Security Solutions Inc (NASDAQ:KTOS) across three ETFs for $317,272, and purchased 7,175 shares of Kodiak AI Inc (KDK) through its ARKQ ...

In trading on Thursday, the iShares U.S. Home Construction ETF is outperforming other ETFs, up about 3.8% on the day. Components of that ETF showing particular strength include shares of LGI Homes, up ...

In the biotech space, ARK acquired 127,184 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) through its ARKK and ARKG ETFs, ...

On Thursday, Jan. 22, 2026, Cathie Wood-led Ark Invest bought $2.4 million in Tempus AI and WeRide while selling $1.6 million ...

Cathie Wood’s ARK Invest repositions toward long-term innovation themes like advanced air mobility, autonomous transport, and gene editing during the last week, while reducing exposure to more mature ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.